Skip to search formSkip to main contentSkip to account menu

Dicumarol

Known as: Bis(4-hydroxycoumarin-3-yl)methane, 2H-1-Benzopyran-2-one, 3,3'-methylenebis(4-hydroxy)-, bis-hydroxycoumarin 
An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
The course of long-term anticoagulant therapy in 114 out-patients has been evaluated over a three-month period. The evaluation… 
1977
1977
1 A group of 114 patients on long-term anticoagulant therapy was studied. The daily maintenance dose of both phenprocoumon… 
1973
1973
THE effect of the dicoumarol drugs on clotting factor biosynthesis is similar to that of vitamin K deficiency, in that the… 
Highly Cited
1968
Highly Cited
1968
A widely used method for the determination of bishydroxycoumarin (BHC) in plasma, which involves extraction of BHC from acidified… 
1962
1962
At the present time, hypoprothrombinemia induced by anticoagulant drugs is the most commonly encountered coagulation defect in… 
Highly Cited
1954
Highly Cited
1954
A DISTURBING feature of the occasional case of fatal hemopericardium following anticoagulant therapy for myocardial infarction is… 
1950
1950
NUMEROUS reports1 2 3 4 5 6 during the past few years have emphasized the value of Dicumarol therapy in reducing the mortality… 
1944
1944
Excerpt Interest in anti-coagulants as therapeutic agents has encouraged the trial of various substances in conditions… 
Highly Cited
1939
Highly Cited
1939
The author 1 developed a quantitative method for the determination of prothrombin based on the principle that the clotting time…